Pfizer collectively addresses 15 therapy areas in the domestic formulations with a portfolio of over 150 products that include therapeutics & vaccines. The company has been continuously restructuring its portfolio in the last few years to improve the productivity of its core brands.
Revenues growth was subdued this quarter due to decline in VMS and Anti-Infective therapies offtake in Q4FY22 on YoY basis.
Equity Capital: 3,207.30 Cr FV: 10.00
| Period | MF Net Purchase / (sold) | FII Net |
|---|---|---|
| LAST 1M | 15,779.50 | 22,156.90 |
| LAST 3M | 54,802.13 | -2,099.03 |
| LAST 6M | 93,089.45 | 78,838.27 |
| LAST 12M | 161,092.98 | 118,023.38 |
| Date | Action Type | Ratio |
|---|---|---|
| Aug 11, 2023 | Dividend | 350 |
| Aug 11, 2023 | Dividend | 50 |
| Sep 19, 2022 | Dividend | 300 |
Pfizer Ltd is in the Pharmaceuticals sector, having the Market Capitalization of worth Rs. 26,896.85 crores, it is incorporated in the year 1986. It has reported consolidated sales of Rs. 749.17 crores in June’2021. The company is listed in the Bombay Stock Exchange (BSE) with the code 500680, and also listed in the National Stock Exchange (NSE) with the code PFIZER.
Pfizer Ltd is the fourth largest multinational pharmaceuticals company in India. Pfizer ltd is a subsidiary of Pfizer Inc. It holds 40% ownership of Pfizer Ltd. Pfizer Ltd is also known for its award-winning manufacturing facility having state-of-the-art technology and the capacity to produce over one billion tablets annually. Some of the many top brands produced by Pfizer are Prevenar 13, Dolonex, Corex, Becosules, Gelusil, etc. Pfizer ltd enjoys a unique advantage as it gets access to Pfizer Inc’s global portfolio of therapies and introduces them into Indian markets. Pfizer ltd is also the first pharmaceutical company to start clinical research in the country. Although Pfizer ltd was incorporated in 1986, it had already entered the Indian markets in 1950 through Dumex ltd. The promoters of the company own 63.92% of the stake in the company, Foreign Institutional Investors (FII) own 1.95%, Domestic Institutional Investors (DII) own 14.96% of the stake, and others (such as public & retail
investors) hold the balance of 19.17%.
In June 2021, quarterly net revenue was Rs. 749.17 crores, which has increased by approximately 45.50 % from Rs. 380.28 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 199.91 crores, which has also increased by nearly 60.63% from a net profit of Rs. 124.45 crores in June 2020. In June 2021, the reported operating profit was at Rs. 666.86 crores, which is also increased by 42.81% as compared to an operating profit of Rs. 466.96 crores for the quarter ending in June 2020. From Rs. 27.20 in June 2020, the EPS of Pfizer has risen to Rs. 43.69 per share in June 2021. PFIZER’s stock closed at Rs. 5879.35 on 18th August’2021 (NSE) and has returned 27.44% in the last six months and 29.38% in the previous year.
The Capital 1802/1901 Plot-C70, G Bl Bandra Kurla Cpx Bandra-E, Mumbai, Maharashtra, 400051
| Tel | : | 91-22-66932000 |
| : | contactus.india:pfizer.com | |
| Website | : | http://www.pfizerindia.com |
Karvy Computershare Pvt Ltd
| AGM Date (Month) | : | Aug |
| Face Value Equity Shares | : | 10 |
| Market Lot Equity Shares | : | 1 |
| BSE Code | : | 500680 |
| NSE Code | : | PFIZER |
| Book Closure Date (Month) | : | |
| BSE Group | : | A |
| ISIN | : | INE182A01018 |
FAQ’s on Pfizer Ltd SharesYou can buy Pfizer Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Pfizer Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Dec 01, 2023 04:06 PM the closing price of Pfizer Ltd was ₹ 4,101.40.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Dec 01, 2023 04:06 PM, the market cap of Pfizer Ltd stood at ₹ 18,763.08.
The latest PE ratio of Pfizer Ltd as of Dec 01, 2023 04:06 PM is 35.08
The latest PB ratio of Pfizer Ltd as of Dec 01, 2023 04:06 PM is 0.17
The 52-week high of Pfizer Ltd is ₹ 4,626.40 while the 52-week low is ₹ 3,408.00
According to analyst recommendations, Pfizer Ltd has a “Buy” rating for the long term.
Download Our App
Invest
